Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,363 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,404)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07240857 | A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer | enrolling by invitation | Early Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06204614 | Drug Screening Using IMD in Bladder Cancer | enrolling by invitation | Early Phase 1 | 18 | Brigham and Women's HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06782399 | Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma(SCC) | enrolling by invitation | Early Phase 1 | 25 | Oliver JonasOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07356466 | Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(FUGES032) | enrolling by invitation | Early Phase 1 | 100 | Fujian Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07316361 | GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer(GYNORYLAQ™) | enrolling by invitation | Early Phase 1 | 40 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07285434 | Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer(Microlyvaq™) | enrolling by invitation | Early Phase 1 | 90 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07023848 | PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors | enrolling by invitation | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07023861 | The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies | enrolling by invitation | Early Phase 1 | 20 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06747832 | INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer(iNK-SCLC) | enrolling by invitation | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 22, 2026source: clinicaltrials